Clinical Trials

PEAK or CGT: A PHASE 3 RANDOMIZED, OPEN-LABEL, MULTICENTER CLINICAL STUDY OF CGT9486+SUNITINIB VS SUNITINIB IN SUBJECTS WITH LOCALLY ADVANCED, UNRESECTABLE OR METASTATIC GASTROINTESTINAL STROMAL TUMORS

Link : https://www.clinicaltrials.gov/ct2/show/NCT05208047
Status : RECRUITING
Population : 1st line GIST for open label bezuclastinib + sunitinib.
Description : Sunitinib +/- CGT9486
PI : A. Razak
Centers Opened : PMH
Phase : III
IIST/Pharma : Pharma